Medication alert for low back pain

Doctors have urged caution against the use of two medications widely prescribed for chronic low back pain after a systematic review of medical evidence found they carry significant risks of adverse effects without any proven benefit.

The available evidence does not support the use of gabapentin and pregabalin for treating chronic low back pain, the doctors based in Canada and India said after reviewing multiple earlier studies comparing these drugs with placebo treatment, or sham pills.

Chronic low back pain is a common health disorder with studies indicating prevalence rates of four in every 100 persons between 24 and 39 years to 20 in every 100 persons between 20 and 59 years. Doctors typically use non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics to treat acute low back pain. But patients with chronic low back pain often receive prescriptions for gabapentin or pregabalin, which have been shown to be helpful in treating nerve-linked pain.

"There is no justification for gabapentin or pregabalin in chronic low back pain that doesn't involve leg pain," says Sriganesh Kamath, an associate professor of neuroanaesthesia at the National Institute of Mental Health and Neurosciences, Bangalore, and member of the research team.

ᐧ

Comments

ICH GCP requires EC members to be independent of investigator and sponsor to avoid conflicts of interest

Can an Ethics Committee member e.g. layman/chairman or anyone in the committee participate in the trial as a subject? Vidya If an Ethics Committee member becomes a trial subject on a trial that he/she was involved in approving then there has been a major conflict of interest. The following situations need to be considered: ● IEC member reviews study without any prior knowledge of the study, votes, and then afterwards is approached by clinical research team to participate. Possibly this is OK but the member should no longer be part of the IEC that reviews that study. This will be difficult in practice, so therefore it is not advisable. ● IEC member already knows about the study and is voting in order to be able to participate. This is clearly not acceptable and made worse if there is additional financial incentive for the study (e.g. volunteer study). ICH GCP requires Ethics Committee members to be independent of the investigator and the sponsor to avoid confl...

Indian government outlines policies on drug pricing to favor poorer patients, and increase clinical trials

The Indian government is looking to review the existing drug price control measures in order to make medicines more affordable in the country, and at increasing the number of clinical trials taking place in the country, reports The Pharma Letter's India correspondent. In a parallel move, the Health Ministry is also preparing a framework for public private partnership to tackle the menace of non-communicable diseases in the country, In a move that could potentially result in affordable Medicare and health security moving to a larger section of the population, the government is considering a rash of policy measures in favor of poor patients. Talks are also on in government circles to abolish clinical trials on proven drugs that have been approved and marketed for at least two years in the European Union, United States, UK, Australia, Canada and Japan. A draft proposal in this regard has been prepared by the Health Ministry. If instituted, it would reduce the time taken to introduce n...

The polypill: Medicine's magic bullet

The capsule costs pennies, contains a simple cocktail of medicines, and halves the number of strokes and heart attacks. Doctors want to hand it out in the first mass medication for the middle-aged in Britain. So why are the big drug companies so uninterested? The magic bullet, containing five medicines in a single capsule, sharply reduced cholesterol and blood pressure levels and has the potential to "halve cardiovascular events in average middle-aged individuals", the researchers say. The finding is a major boost for a medication with huge potential against the worldwide epidemic of heart disease and stroke. Doctors say that, if further trials prove successful, all men aged over 50 and women aged over 60 should be offered the pill in what would be the first example of mass medication for the middle-aged in Britain. Yet no Western pharmaceutical company has shown interest in developing the so-called polypill because it does not promise big profits. It would sell for pennies b...

My Clinical Trials Diary

Search This Blog